Option Care Health Jumps 33 Percent to $31 After McKesson and CD&R Agree to Take It Private for $5.8 Billion

Option Care Health (OPCH) shares rose 33% to $31.02 after McKesson and Clayton Dubilier & Rice agreed to take it private for $5.8 billion, including debt. The offer is $32.05 per share, a 37.1% premium over Monday's close. CD&R will hold a majority stake, while McKesson will invest $1.4 billion for a 49% stake, with an option to buy the rest later. The deal is expected to close in the first half of 2027, subject to approvals. Option Care is a major provider of home infusion therapy.

Original reporting
Published Oct 6, 2026, 2:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 6, 2026, 4:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Option Care Health Jumps 33 Percent to $31 After McKesson and CD&R Agree to Take It Private for $5.8 Billion — source image
Decision brief

The 30-second read

$OPCHBullishHigh
01

Why it matters

The deal adds a new vertical for McKesson and provides a cash exit for Option Care shareholders at a premium, likely driving short‑term upside for OPCH and modest strategic interest for MCK.

02

Market read

A $5.8 bn take‑private deal with a 33% share price jump creates immediate trading opportunities and signals broader consolidation trends in healthcare services.

03

What to watch

Potential integration challenges between a distributor and a service provider may affect long‑term value creation.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Option Care Health is the largest U.S. provider of home and alternate‑site infusion therapy; McKesson distributes specialty drugs and seeks to expand into services.

Company-level read

Ticker impact

$OPCHBullishHigh confidence
Context

Option Care Health shares jumped 33% after the announcement of a $5.8 bn take‑private deal with McKesson and CD&R at $32.05 per share.

Expected impact

likely upward pressure as market prices in the deal premium

Evidence & confidence

Deal announced at a 37% premium, immediate 33% price jump, and no competing bids suggest near‑term upside.

$MCKNeutralMedium confidence
Context

McKesson is investing $1.4 bn for a 49% stake in Option Care Health as part of the $5.8 bn transaction.

Expected impact

modest positive bias as investors assess strategic expansion

Evidence & confidence

Investment is sizable but spread over years; market reaction likely muted compared with Option Care’s share surge.

Market effects

Healthcare services sector may see increased M&A interest as distributors seek vertical integration.

U.S. healthcare and specialty drug distribution markets could tighten as integration proceeds.

Large private‑equity deal highlights continued capital flow into U.S. health‑care assets.

Counterpoint

Regulatory scrutiny or shareholder dissent could delay or derail the transaction, causing a pull‑back in Option Care’s price.

Key entities

  • Option Care Health

    U.S. home infusion therapy provider being taken private.

  • McKesson Corp.

    Pharmaceutical distributor investing in Option Care.

  • Clayton Dubilier & Rice

    Lead private‑equity sponsor acquiring majority stake.

Related articles

$MCKHighAI 8/10

Healthcare providers & services stocks Q3 results: Benchmarking McKesson

McKesson (MCK) reported Q3 revenue of $111B, up 7.6% YoY, beating estimates. LifeStance Health (LFST) saw 25.3% revenue growth, while Brookdale (BKD) reported a 12.4% decline. Elevance Health (ELV) and The Pennant Group (PNTG) also released Q3 results, with mixed outcomes. Sector revenues beat estimates by 2.2%, and stocks are up 4.4% on average since earnings.

$MCKMedAI 8/10

Sales of Pharmaceuticals, GLP-1s Send McKesson Shares to New Highs

McKesson (MCK), the largest U.S. pharmaceutical distributor, reported Q2 2027 revenue of $111B (up 8% YoY), driven by North American pharmaceuticals and GLP-1 distribution. Operating profit rose 13% to $1.9B, and adjusted EPS increased 18% to $11.68. The company raised full-year EPS guidance to up to $46.40, implying 19% growth. MCK shares are up 32% YTD, with strong institutional support and long-term growth trends.